Talnetant
Подписчиков: 0, рейтинг: 0
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| ECHA InfoCard | 100.236.526 |
| Chemical and physical data | |
| Formula | C25H22N2O2 |
| Molar mass | 382.463 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
|
| |
Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several functions (primarily treatment of irritable bowel syndrome, despite a 2007 study finding no statistically significant improvement in rectal hypersensitivity over placebo). Its use as a potential antipsychotic drug for the treatment of schizophrenia has also been discontinued.